Ontology highlight
ABSTRACT:
SUBMITTER: Brossel H
PROVIDER: S-EPMC8269013 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
Brossel Hélène H Fontaine Alexis A Hoyos Clotilde C Jamakhani Majeed M Willems Mégane M Hamaidia Malik M Willems Luc L
Cancers 20210627 13
Immunotherapy based on two checkpoint inhibitors (ICI), programmed cell death 1 (PD-1, Nivolumab) and cytotoxic T-lymphocyte 4 (CTLA-4, Ipilimumab), has provided a significant improvement in overall survival for malignant mesothelioma (MM). Despite this major breakthrough, the median overall survival of patients treated with the two ICIs only reached 18.1 months vs. 14 months in standard chemotherapy. With an objective response rate of 40%, only a subset of patients benefits from immunotherapy. ...[more]